Head-To-Head Analysis: NovAccess Global (OTCMKTS:XSNX) versus Roivant Sciences (NASDAQ:ROIV)

NovAccess Global (OTCMKTS:XSNX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares NovAccess Global and Roivant Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NovAccess Global	N/A	N/A	N/A
Roivant Sciences	-1,839.58%	-16.43%	-15.68%

Insider & Institutional Ownership

64.8% of Roivant Sciences shares are owned by institutional investors. 1.4% of NovAccess Global shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

NovAccess Global has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for NovAccess Global and Roivant Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovAccess Global	0	0	0	0	0.00
Roivant Sciences	0	2	7	1	2.90

Roivant Sciences has a consensus target price of $25.19, suggesting a potential upside of 5.74%. Given Roivant Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Roivant Sciences is more favorable than NovAccess Global.

Valuation and Earnings

This table compares NovAccess Global and Roivant Sciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovAccess Global	N/A	N/A	-$4.72 million	($0.11)	N/A
Roivant Sciences	$29.05 million	570.30	-$171.98 million	($0.56)	-42.54

NovAccess Global has higher earnings, but lower revenue than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than NovAccess Global, indicating that it is currently the more affordable of the two stocks.

Summary

Roivant Sciences beats NovAccess Global on 7 of the 13 factors compared between the two stocks.

About NovAccess Global

NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient’s immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.